Sutro Biopharma Net Income vs. Return On Equity
| STRO Stock | USD 15.63 1.65 11.80% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -11.5 M | Current Value -56.9 M | Quarterly Volatility 26 M |
For Sutro Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sutro Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sutro Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sutro Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sutro Biopharma over time as well as its relative position and ranking within its peers.
Check out World Market Map. Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Sutro Biopharma Return On Equity vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sutro Biopharma's current stock value. Our valuation model uses many indicators to compare Sutro Biopharma value to that of its competitors to determine the firm's financial worth. Sutro Biopharma is rated below average in net income category among its peers. It is rated below average in return on equity category among its peers . Sutro Biopharma reported last year Net Loss of (204.71 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sutro Biopharma's earnings, one of the primary drivers of an investment's value.Sutro Return On Equity vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Sutro Biopharma |
| = | (227.46 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Sutro Biopharma |
| = | -18.1 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Sutro Return On Equity Comparison
Sutro Biopharma is currently under evaluation in return on equity category among its peers.
Sutro Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sutro Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sutro Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Sutro Biopharma's change in net profit over the period of time. It can combine multiple indicators of Sutro Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 44.9 K | 47.1 K | |
| Net Interest Income | 15.4 M | 16.1 M | |
| Interest Income | 51.1 M | 53.6 M | |
| Operating Income | -214.6 M | -203.9 M | |
| Net Loss | -204.7 M | -194.5 M | |
| Income Before Tax | -202.6 M | -192.5 M | |
| Total Other Income Expense Net | 15.4 M | 16.1 M | |
| Net Loss | -107.3 M | -101.9 M | |
| Net Loss | -204.7 M | -194.5 M | |
| Income Tax Expense | 2.7 M | 5.3 M | |
| Non Operating Income Net Other | 519.3 K | 493.3 K | |
| Change To Netincome | 14.6 M | 15.3 M | |
| Net Loss | (34.05) | (32.34) | |
| Income Quality | 0.76 | 0.80 | |
| Net Income Per E B T | 1.16 | 1.19 |
Sutro Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sutro Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sutro Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sutro Biopharma's important profitability drivers and their relationship over time.
Sutro Biopharma Earnings Estimation Breakdown
The calculation of Sutro Biopharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Sutro Biopharma is estimated to be -0.4057 with the future projection ranging from a low of -0.6 to a high of -0.19. Please be aware that this consensus of annual earnings estimates for Sutro Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.6 Lowest | Expected EPS | -0.19 Highest |
Sutro Biopharma Earnings Projection Consensus
Suppose the current estimates of Sutro Biopharma's value are higher than the current market price of the Sutro Biopharma stock. In this case, investors may conclude that Sutro Biopharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Sutro Biopharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 10 | 52.27% | 0.0 | -0.4057 | -2.6 |
Sutro Biopharma Earnings per Share Projection vs Actual
Actual Earning per Share of Sutro Biopharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Sutro Biopharma predict the company's earnings will be in the future. The higher the earnings per share of Sutro Biopharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Sutro Biopharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Sutro Biopharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Sutro Biopharma should always be considered in relation to other companies to make a more educated investment decision.Sutro Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Sutro Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.4 | -0.67 | -0.27 | 67 | ||
2025-08-07 | 2025-06-30 | -0.41 | -0.14 | 0.27 | 65 | ||
2025-05-12 | 2025-03-31 | -0.92 | -0.91 | 0.01 | 1 | ||
2025-03-24 | 2024-12-31 | -0.955 | -0.6332 | 0.3218 | 33 | ||
2024-11-11 | 2024-09-30 | -0.73 | -0.4982 | 0.2318 | 31 | ||
2024-08-13 | 2024-06-30 | -0.79 | -0.59 | 0.2 | 25 | ||
2024-05-13 | 2024-03-31 | -0.92 | -0.95 | -0.03 | 3 | ||
2024-03-25 | 2023-12-31 | -0.82 | 0.52 | 1.34 | 163 | ||
2023-11-13 | 2023-09-30 | -0.74 | -0.81 | -0.07 | 9 | ||
2023-08-10 | 2023-06-30 | -0.73 | -0.64 | 0.09 | 12 | ||
2023-05-15 | 2023-03-31 | -0.81 | -0.85 | -0.04 | 4 | ||
2023-03-30 | 2022-12-31 | -0.62 | -0.68 | -0.06 | 9 | ||
2022-11-08 | 2022-09-30 | -0.74 | -0.37 | 0.37 | 50 | ||
2022-08-08 | 2022-06-30 | -0.46 | -0.55 | -0.09 | 19 | ||
2022-05-09 | 2022-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2022-02-28 | 2021-12-31 | -0.69 | -0.83 | -0.14 | 20 | ||
2021-11-10 | 2021-09-30 | -0.65 | -0.67 | -0.02 | 3 | ||
2021-08-09 | 2021-06-30 | -0.41 | -0.13 | 0.28 | 68 | ||
2021-05-07 | 2021-03-31 | -0.6 | -0.66 | -0.06 | 10 | ||
2021-03-18 | 2020-12-31 | -0.57 | -1.48 | -0.91 | 159 | ||
2020-11-05 | 2020-09-30 | -0.51 | 0.45 | 0.96 | 188 | ||
2020-08-06 | 2020-06-30 | -0.64 | -0.59 | 0.05 | 7 | ||
2020-05-11 | 2020-03-31 | -0.69 | -0.84 | -0.15 | 21 | ||
2020-03-16 | 2019-12-31 | -0.69 | -0.64 | 0.05 | 7 | ||
2019-11-08 | 2019-09-30 | -0.65 | -0.56 | 0.09 | 13 | ||
2019-08-14 | 2019-06-30 | -0.68 | -0.6 | 0.08 | 11 | ||
2019-05-16 | 2019-03-31 | -0.63 | -0.62 | 0.01 | 1 | ||
2018-12-31 | 2018-12-31 | -0.63 | -0.26 | 0.37 | 58 | ||
2018-11-14 | 2018-09-30 | -0.16 | -21.26 | -21.1 | 13187 | ||
2018-09-26 | 2018-06-30 | 0 | -1.37 | -1.37 | 0 |
Use Sutro Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Sutro Biopharma Pair Trading
Sutro Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sutro Biopharma position
In addition to having Sutro Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Baby Boomer Prospects Thematic Idea Now
Baby Boomer Prospects
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
To fully project Sutro Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sutro Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sutro Biopharma's income statement, its balance sheet, and the statement of cash flows.